Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells.
about
Substituted pyrrolo[2,3-d]pyrimidines as Cryptosporidium hominis thymidylate synthase inhibitorsCryptosporidium infection in solid organ transplantationNitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infectionsNitazoxanide: a new broad spectrum antiparasitic agentDicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlationsA screening pipeline for antiparasitic agents targeting cryptosporidium inosine monophosphate dehydrogenaseCryptosporidium Lactate Dehydrogenase Is Associated with the Parasitophorous Vacuole Membrane and Is a Potential Target for Developing TherapeuticsCryptosporidium-malnutrition interactions: mucosal disruption, cytokines, and TLR signaling in a weaned murine model.Inhibitory activities of epidermal growth factor receptor tyrosine kinase-targeted dihydroxyisoflavone and trihydroxydeoxybenzoin derivatives on Sarcocystis neurona, Neospora caninum, and Cryptosporidium parvum development.Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitroNitazoxanide in treatment of Helicobacter pylori: a clinical and in vitro study.Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growthCurrent therapeutics, their problems, and sulfur-containing-amino-acid metabolism as a novel target against infections by "amitochondriate" protozoan parasites.Transient neonatal Cryptosporidium parvum infection triggers long-term jejunal hypersensitivity to distension in immunocompetent rats.In vitro parasiticidal effect of Nitazoxanide against Echinococcus multilocularis metacestodesDrug resistance in the sexually transmitted protozoan Trichomonas vaginalis.Simultaneous quantification of tizoxanide and tizoxanide glucuronide in mouse plasma by liquid chromatography-tandem mass spectrometry.Nitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: results of the United States compassionate use program in 365 patients.Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.Novel non-active site inhibitor of Cryptosporidium hominis TS-DHFR identified by a virtual screenValidation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis.Efficacy of ginkgolic acids against Cryptosporidium andersoni in cell culture.A nanotherapy strategy significantly enhances anticryptosporidial activity of an inhibitor of bifunctional thymidylate synthase-dihydrofolate reductase from Cryptosporidium.Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase.In-vitro transfer of nitazoxanide across the intestinal epithelial barrier.Tizoxanide pyridine monosolvate.The therapeutic efficacy of azithromycin and nitazoxanide in the acute pig model of Cryptosporidium hominisEvaluation of new thiazolide/thiadiazolide derivatives reveals nitro group-independent efficacy against in vitro development of Cryptosporidium parvum.Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru.Nitazoxanide: a new thiazolide antiparasitic agent.Efficacy of nitazoxanide and paromomycin in biliary tract cryptosporidiosis in an immunosuppressed gerbil model.
P2860
Q27679459-A8FA7343-C396-4395-A467-4A8AC4F77CC9Q28069815-84619AAE-B9AA-455B-A75A-0AE4AE18FB99Q28236279-8DC9A7C7-E809-4A03-9647-2AE63C08B38CQ28287647-D758AEB9-3AB7-40A2-BEDE-8EC64B5521D0Q28364098-9D728D6A-E9AD-4A9E-B273-C7980C2D6357Q28475058-EA86C1EA-0ED9-4414-9A19-2A9612EFBE60Q28550913-F2580AC0-79D1-4620-846A-39A4B2C2166DQ30423711-93295AA3-0494-47F2-A691-EE943CB467DDQ34123703-C4713AEF-C902-42FB-A3E8-86F7CEA579D5Q34123709-6B448CF0-304A-4052-9C23-6339FC5E7EE6Q34230254-8F1AD5E3-F808-4FD2-A839-4CADAC557C39Q34574121-97B27074-7C50-46FB-AF28-64FC6BC1B42BQ34601985-35AF35C8-F29F-4258-BA3D-9A056727B2DEQ34721062-818468B2-0F59-4553-A0BB-99E88641675CQ34822604-AFBA99AD-02F6-4EC9-9DD9-79CA00F2B5E5Q35219218-4C43C651-2C68-4FB6-9E37-23A09AF7BA09Q35997175-32AF1543-2FCA-4EA1-B676-7C806AA54C33Q36570821-D7C594E9-6C30-47BF-9639-22E408829239Q36870805-BFC7E10D-1545-48FA-803A-4C357DC08745Q37117303-00A02C6F-84A2-448D-84CC-9E502EA44E07Q37643702-C7D04902-54EC-4C70-9DF3-476F0D32C441Q39545463-BF092BC3-DF03-49D6-A095-49A7A64403BFQ40143707-6D8D77A9-4E5B-4C5C-9418-FB5C00617ED1Q40524360-2D7C8A10-D743-4564-91EF-F7F83D2A4FDDQ40694723-4829B18C-B69E-4DEB-945E-A1EBE7663A09Q41910613-4757F223-5CB3-47E9-AF6B-B6EDCB1EEAACQ41991627-A964B024-9E1C-479E-9888-CE641533BC32Q42114388-E95E6FE3-B4A7-455C-9F79-FB477A0288A3Q43734573-F0CCF353-A611-4D57-8503-8F89F3BB1BDBQ46404981-7DB76205-45DF-4236-ADBF-8E45DB7B97E6Q46856450-C7435474-72B0-4CA0-910C-9B2AE204B96C
P2860
Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Efficacy of nitazoxanide, tizo ...... ected HCT-8 enterocytic cells.
@en
type
label
Efficacy of nitazoxanide, tizo ...... ected HCT-8 enterocytic cells.
@en
prefLabel
Efficacy of nitazoxanide, tizo ...... ected HCT-8 enterocytic cells.
@en
P2093
P356
P1476
Efficacy of nitazoxanide, tizo ...... ected HCT-8 enterocytic cells.
@en
P2093
P356
10.1093/JAC/46.1.57
P407
P577
2000-07-01T00:00:00Z